Two Conditions, One Stimulation Target: rTMS for Chronic Low Back Pain With Insomnia
- DLPFC-rTMS (1 Hz, 1500 pulses, 10 sessions) significantly reduced both pain intensity AND insomnia severity compared to sham — the first RCT targeting comorbid chronic pain + insomnia with rTMS (n = 36) [Asia/Hong Kong]
- Both M1 and DLPFC stimulation reduced pain intensity vs. sham, but only DLPFC-rTMS additionally improved objective sleep (wake after sleep onset) and temporal summation of pain
- DLPFC-rTMS enhanced descending pain inhibitory pathways — the analgesic effect is not just subjective, it is measurable in pain processing circuitry
- Zero attrition, no serious adverse events — high feasibility and acceptability for a two-week, 10-session protocol
Chronic low back pain and insomnia co-occur in 50–80% of cases. They reinforce each other: pain disrupts sleep, poor sleep amplifies pain sensitivity. Yet most treatments target one or the other. This Hong Kong Polytechnic University RCT is the first to test whether a single rTMS protocol can address both simultaneously — and the DLPFC target emerges as the winner.
Why DLPFC beats M1 here
Both motor cortex (M1) and dorsolateral prefrontal cortex (DLPFC) stimulation reduced pain. But only DLPFC additionally reduced insomnia severity and objective wake-after-sleep-onset — the minutes of wakefulness measured by actigraphy, not just self-report.
The mechanism is plausible: DLPFC is a hub for top-down regulation of both pain processing and sleep-wake regulation. Stimulating it addresses the shared executive control deficit that allows both pain catastrophizing and sleep-onset rumination to persist. M1 stimulation modulates pain circuitry directly but does not reach the cognitive-emotional loop that maintains insomnia.
The pain processing finding
DLPFC-rTMS also reduced temporal summation of pain — a marker of central sensitization. This means the treatment is not just masking pain perception; it is modifying the spinal cord's pain amplification mechanism. For chronic pain patients, this is the difference between "feeling better" and "processing pain differently."
For your practice
For clinicians with rTMS access treating chronic pain populations: screen for comorbid insomnia. If both are present, DLPFC targeting may be preferable to M1 — it addresses both conditions with a single protocol. The parameters are practical: 1 Hz, 1500 pulses, 10 sessions over two weeks. For referral: this is a pilot (n = 36), but zero attrition and no serious AEs suggest the protocol is well-tolerated. Larger confirmatory trials are needed before clinical adoption.
Why treat pain and insomnia separately when a single brain target can address the shared circuit that maintains both?
Small pilot sample (n = 36, 12 per group). Short follow-up (one month). No long-term durability data. Sham rTMS may not perfectly mimic active stimulation. Hong Kong university hospital setting may not generalize.